The sponsorships program is a great opportunity to reach many of the ECC delegates and deliver the knowledge and awareness of your product or service. There are a number of sponsorship packages available. The ECC Congress is planned as a hybrid event but we are also prepared for a traditional on-site form. Detailed information can be found in below documents:

Sponsor's offer ECC 2021 English

Oferta sponsorska ECC2021 w języku polskim

For further information please contact:

Below we would like to present you the 43rd Europan Congress of Cytology Sponsors!

TECHNOLOGICAL PARTNER Olympus Polska sp. z o.o.

Workshops conducted during the Congress will use Olympus microscopes and the Olympus VS-200 virtual microscopy system.

More information about the system can be found at: https://www.olympus-lifescience.com/en/solutions-based-systems/vs200/

GOLD and Lunch Symposium Sponsor - 3DHISTECH

Lunch Symposium - Monday, 4th October, 13:15 - 14:15, Auditorium Hall (Poland time zone)

The Digital Pathology Company

3DHISTECH is dedicated to providing clinical pathologists, researchers and universities with digital pathology solutions to facilitate quick and accurate diagnostics, supporting medical discoveries and fostering education. Cytology slides pose different obstacles in whole-slide imaging compared to tissuepathology slides. While a single focal plane may be sufficient for tissue samples, cytology slides are thicker, potentially requiring multiple focal planes for adequate diagnostic information.

At the ECC in Wroclaw, we will showcase our full line of PANNORAMIC® Diagnostic Scanners dedicated for routine pathology: the PANNORAMIC® Flash Desk DX, the PANNORAMIC® 250 Flash III DX and the PANNORAMIC® 1000 DX – all of which ensure excellent image quality.

SILVER and Lunch Symposium Sponsor - Zhiwei Morphogo

Lunch Symposium - Tuesday, 5th October, 13:15 - 14:15, Auditorium Hall (Poland time zone)

Morphogo is a high-tech company specializing in the application of artificial intelligence (AI) technology to cytopathological diagnosis. With technological innovation as the core, the company cooperates with renowned medical institutions around the world to build an international multi-center scientific research framework. The AI-aided bone marrow cytomorphology analysis and diagnosis system independently developed by Morphogo is a breakthrough in the application of AI technology to the field of bone marrow aspirate smear morphology examination, significantly reducing the labor intensity of morphology experts and improving the objectivity and consistency of morphology examination.
Now, the company is actively expanding product lines including analysis of peripheral blood, urine, pleuroperitoneal fluid and cerebrospinal fluid. The company aims to use a fully automated digital slide generation system and artificial intelligence to assist in changing the conventional cytopathological analysis and diagnosis, and create a new pathological environment driven by the concept of “to revolutionize conventional medical examination with artificial intelligence”.

AI-Aided Bone Marrow Cytomorphology Analysis and Diagnosis System (Morphogo) is developed by Hangzhou Zhiwei Information&Techonlogy Company. The system automatically digitizes bone marrow smears by fine whole slide scanning under 40x objective, and it identifies and classifies nucleated cells in the field of view under 100x oil lens utilizing artificial intelligence. It is expected to realize automatic classification of 269 types of nucleated cells and multiple statistical methods such as calculating cell percentages by ANC (all nucleated cells), WBC (white blood cells), NEC (non-erythroid cells), or cell linage. It is the world’s leading medical device for cytopathology and bone marrow cell morphology.
This device has been tested in 19 well-known medical institutions both domestic and overseas. The accuracy of cell classification reaches 90%. At present, it has obtained a medical device manufacturing and sales license from PMDA in Japan. In Europe, it has obtained CE-mark. In China, clinical trials of the NMPA medical device registration had been done by the end of 2020, and the approval is expected to be achieved in the first half-year of 2021.


We’re an innovative medical technology company whose purpose is to enable healthier lives everywhere, every day. While we discover and develop groundbreaking products and services that benefit everyone, we are especially passionate about those that advance women’s health and well-being. We are also a company that prospers and grows, which is why we’ve been able to expand our offerings to benefit even more people and champion women’s health.

What powers our growth across Breast & Skeletal Health, Diagnostic Solutions and GYN Surgical Solutions is also what differentiates us: the exceptional, clinically proven ability of our products to detect, diagnose and treat illnesses and other health conditions earlier and better. This clinical superiority creates high expectations, which we fulfill by always challenging ourselves to improve health through better technology, education and market acces.

BRONZE Sponsor - Becton, Dickinson and Company

BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care.
For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/ and Twitter @BDandCo.

WI-FI Sponsor - Imstar-Dx 

The automated digital pathology complete solutions’ Company. We are a highly innovative company, based in Paris France, serving our customers worldwide, directly or through distributors.Imstar-Dx mission is to design, develop and market a comprehensive solution for digital cytology and pathology, focused on cancer in-vitro diagnosis. We combine 25 years of experience in high-quality virtual slide design, cellular and tissue’ tumoral regions detection, and characterization, as well as markers quantification, embedded in our solution.

We offer to the Cytopathologists community PathoScan VS-Emage and PathoScan T-M products for:
Virtual slides: Far beyond slide scanning, an “a la carte” digital workflow, multifunctional viewer with perfect focus on all pixels of tissue or cytology virtual slides, at a low cost per slide, no dependency from 3rd parties.
Automated Tumor Markers Quantification: A range of Software modules for high-throughput assisted diagnostic of over 15 markers, in IHC, CISH, FISH, IF techniques, single or double labelling.

More information about the system can be found at: https://www.imstar-dx.com


Karger Publishers, headquartered in Basel, Switzerland, is a globally active publishing house in Health Sciences. It is independent and family-run in the fourth generation with 240 employees worldwide. S. Karger AG consists of the publishing company Karger Publishers (est. 1890) and the International Subscription Agency Karger Libri (est. 1960). Chairwoman and Publisher Gabriella Karger leads the publishing company and S. Karger AG together with CEO Daniel Ebneter and COO Andre Janssen. In addition to the company headquarters in Basel, Switzerland and subsidiaries in Freiburg, Germany and Abingdon, United Kingdom, there are Karger regional offices or representatives in Australia, China, France, India, Japan, Malaysia, Mexico, the Russian Federation, the United Arab Emirates, and the United States.

Thermo Fisher Scientific Inc.

Lunch Symposium - Wednesday, 6th October, 13:15 - 13:30, Auditorium Hall (Poland time zone)

Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with annual revenue exceeding $30 billion. Thermo Fisher Scientific supplies innovative solutions for the world’s pharmaceutical and biopharmaceutical industries. With applications that span the drug development process – from drug discovery through large-scale commercial production – we provide a broad range of products and services including single-use technologies, customized fluid transfer systems, high-quality media and sera, freezing and storage equipment, and innovative consumables and reagents, purification, and analytics. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Ion Torrent™ Oncomine™ liquid biopsy assays are highly sensitive, multibiomarker next-generation sequencing (NGS) assays that enable molecular insights into tumor evolution and detection of primary driver and resistance mutations for clinical research.

Our global team of more than 80,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon. For more information, please visit www.thermofisher.com.

This website uses cookies to allow the registration of event participants and service related processes. By using this site you agree on the use of cookies according to the current browser settings. Accept